#1 Clinical Trials Search in Europe

Pehero

A new drug called Pehero is currently being studied in clinical trials for its potential to treat mild to moderate psoriasis. This article will provide an overview of the ongoing research, including the study’s objectives, eligibility criteria, and expected outcomes. The information presented is based on a Phase 2B clinical trial, which aims to evaluate the effectiveness and safety of Pehero in patients with mild to moderate psoriasis.

Table of Contents

What is PEHERO?

PEHERO, also known as HRO350 or Phospholipid esters from herring roe oil (PEHeRo), is a new medication being studied for the treatment of mild to moderate psoriasis[1]. It is an oral medication that comes in the form of soft capsules[1]. PEHERO is currently undergoing clinical trials to evaluate its effectiveness and safety in treating psoriasis, a chronic skin condition characterized by red, scaly patches on the skin.

How PEHERO Works

While the exact mechanism of action is not fully described in the provided information, PEHERO is derived from herring roe oil[1]. Fish oils, particularly those rich in omega-3 fatty acids, have been studied for their potential anti-inflammatory properties, which may help in managing psoriasis symptoms. However, it’s important to note that more research is needed to fully understand how PEHERO works in treating psoriasis.

Clinical Trial Details

The clinical trial for PEHERO, known as the ‘HeROPA’ study, is a Phase 2B study designed to evaluate the effectiveness and safety of the medication[1]. Here are some key details about the trial:

  • Study Type: The trial is a multicenter, randomized, double-blind, placebo-controlled study. This means that participants are randomly assigned to either receive PEHERO or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
  • Dosage: The study is testing two different daily doses of PEHERO: 1050 mg and 2100 mg[1].
  • Duration: The primary endpoint is measured at 26 weeks, with a potential long-term safety evaluation for up to 52 weeks[1].
  • Main Objective: The primary goal is to evaluate the clinical efficacy of PEHERO compared to placebo in patients with mild-to-moderate psoriasis[1].

Eligibility Criteria

To participate in the PEHERO clinical trial, patients must meet certain criteria. Some of the key inclusion criteria are:

  • Age 18 years or older[1]
  • Diagnosis of chronic, active plaque psoriasis of mild to moderate severity[1]
  • Psoriasis Area and Severity Index (PASI) score between 3 and 10[1]
  • Body Surface Area (BSA) affected by psoriasis of 3% or more[1]
  • Static Physician’s Global Assessment (sPGA) score between 2 and 4[1]

There are also several exclusion criteria, including recent use of other psoriasis treatments and known allergies to fish or vegetable oils[1].

Potential Benefits

The clinical trial aims to measure several potential benefits of PEHERO, including:

  • Reduction in psoriasis severity: The primary goal is to achieve at least a 50% reduction in the PASI score (PASI50) after 26 weeks of treatment[1].
  • Improvement in scalp psoriasis: The study will measure changes in scalp psoriasis using the Scalp PGA (ScPGA) Scale[1].
  • Enhanced quality of life: The trial will assess improvements in quality of life using the Dermatology Life Quality Index (DLQI)[1].
  • Reduction in psoriasis symptoms: The Psoriasis Symptom Inventory (PSI) will be used to measure changes in psoriasis symptoms[1].

Safety Considerations

As with any clinical trial, the safety of PEHERO is a primary concern. The study will monitor several safety aspects, including:

  • Adverse events: Any unexpected medical occurrences during the trial will be recorded and evaluated[1].
  • Laboratory tests: Biochemical and hematological tests will be conducted to monitor participants’ health[1].
  • Discontinuation rates: The number of participants who stop taking the medication will be tracked[1].

It’s important to note that PEHERO is still in the clinical trial phase, and its long-term safety and effectiveness are still being evaluated. Patients interested in this treatment should consult with their healthcare provider and consider participating in clinical trials if eligible.

Aspect Details
Drug Name Pehero (HRO350)
Condition Mild to moderate psoriasis
Trial Phase Phase 2B
Study Design Multicenter, randomized, double-blind, placebo-controlled, dose-finding
Dosages Tested 1050 mg and 2100 mg daily (oral)
Primary Endpoint Proportion of patients achieving PASI50 at week 26
Key Secondary Endpoints sPGA, BSA, DLQI, PSI, Treatment Satisfaction Score
Safety Assessments Adverse events, lab tests, discontinuation rates
Maximum Treatment Duration 52 weeks

FAQ

  • What is Pehero and how is it being studied? Pehero is a new drug being investigated for the treatment of mild to moderate psoriasis. It is currently being studied in a Phase 2B clinical trial called the 'HeROPA' study. The trial is testing two different oral doses of Pehero (1050 mg and 2100 mg daily) compared to a placebo to determine its effectiveness and safety.
  • Who can participate in the Pehero clinical trial? The trial is open to adults (18 years and older) with a diagnosis of chronic, active plaque psoriasis of mild to moderate severity. Participants must have specific scores on psoriasis assessment scales and must not have received certain treatments for a specified period before the trial. There are also other inclusion and exclusion criteria that potential participants must meet.
  • What are the main goals of the Pehero clinical trial? The primary goal of the trial is to evaluate the clinical effectiveness of two oral doses of Pehero compared to a placebo in patients with mild to moderate psoriasis. The study also aims to assess the long-term safety of Pehero and to select the recommended dose for future Phase 3 trials.
  • How long does the Pehero clinical trial last? The trial duration is not explicitly stated in the provided information. However, the primary endpoint is measured at week 26, suggesting that the initial treatment period is at least 26 weeks (about 6 months). The maximum treatment period mentioned is 52 weeks (1 year), which may include a long-term safety follow-up.
  • What are the main outcomes being measured in the Pehero trial? The main outcome being measured is the proportion of patients who achieve a 50% or greater reduction in their Psoriasis Area and Severity Index (PASI) score after 26 weeks of treatment. Other outcomes include changes in various psoriasis assessment scales, quality of life measures, treatment satisfaction, and safety indicators such as adverse events and laboratory test results.

Ongoing Clinical Trials on Pehero

  • Study on the Effectiveness and Safety of HRO350 for Patients with Mild-to-Moderate Psoriasis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Finland Germany Norway Poland

Glossary

  • Psoriasis: A chronic skin condition characterized by red, itchy, and scaly patches on the skin. It occurs when skin cells grow too quickly, causing a buildup on the surface of the skin.
  • Pehero: The investigational drug being studied in this clinical trial for the treatment of mild to moderate psoriasis. It is derived from herring roe oil and is taken orally in capsule form.
  • Phase 2B trial: A stage of clinical research that aims to determine the effectiveness and optimal dosage of a new drug before moving on to larger, more definitive Phase 3 trials.
  • Placebo: An inactive substance that looks like the drug being tested but contains no active ingredient. It is used as a comparison to evaluate the true effects of the investigational drug.
  • PASI (Psoriasis Area and Severity Index): A tool used to measure the severity and extent of psoriasis. It combines the assessment of the severity of lesions and the area affected into a single score.
  • PASI50: A 50% reduction in the PASI score, which indicates a significant improvement in psoriasis symptoms.
  • Body Surface Area (BSA): A measurement of the percentage of the body affected by psoriasis.
  • Static Physician's Global Assessment (sPGA): A tool used by doctors to evaluate the overall severity of a patient's psoriasis at a single point in time.
  • Dermatology Life Quality Index (DLQI): A questionnaire that measures the impact of skin diseases on a patient's quality of life.
  • Psoriasis Symptom Inventory (PSI): A patient-reported tool that assesses the severity of psoriasis symptoms.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-hro350-for-patients-with-mild-to-moderate-psoriasis/